Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Condition:   Head and Neck Neoplasms
Interventions:   Biological: Pembrolizumab;   Drug: Placebo;   Drug: Cisplatin;   Radiation: Accelerated Fractionation (AFX) Radiotherapy;   Radiation: Standard Fractionation (SFX) Radiotherapy
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting - verified February 2017

http://ift.tt/2l0kUhz